Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MK-6598 |
| Synonyms | |
| Therapy Description |
MK-6598 inhibits IL4I1, potentially resulting in antitumor activity (Cancer Res (2025) 85 (8_Supplement_2): CT074). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MK-6598 | MK 6598|MK6598 | MK-6598 inhibits IL4I1, potentially resulting in antitumor activity (Cancer Res (2025) 85 (8_Supplement_2): CT074). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05594043 | Phase I | MK-6598 + Pembrolizumab MK-6598 | A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001) | Completed | USA | CHE | CAN | 0 |